Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of ADR-001 adipose-derived stem cells for idiopathic pulmonary fibrosis
jRCT2063200007Phase 1Recruiting
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Start
- Jun 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ADR-001 in idiopathic pulmonary fibrosis (IPF), sponsored by Rohto Pharmaceutical Co., Ltd. Primary endpoint: Safety: maximum tolerated dose and dose-limiting toxicity. Started Jun 2020; status: recruiting.
02
Drugs
ADR-001
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on jRCT2063200007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2063200007.